XML 38 R26.htm IDEA: XBRL DOCUMENT v3.21.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
9 Months Ended
Sep. 30, 2021
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  
Net Income (Loss) Per Share

 

 

For the Three Months Ended September 30,

(Unaudited)

 

 

 

2021

 

 

2020

 

Net Income (Loss)

 

$(486,558)

 

$1,019,300

 

Net income (loss) attributable to common shareholders

 

$(486,558)

 

$1,019,300

 

Weighted average number of shares of common stock outstanding:

 

 

 

 

 

 

 

 

Basic

 

 

16,843,045

 

 

 

16,741,622

 

Diluted

 

 

16,843,045

 

 

 

18,593,255

 

Net income (loss) attributable to common shareholders per share:

 

 

 

 

 

 

 

 

Basic

 

$(0.03)

 

$0.06

 

Diluted

 

$(0.03)

 

$0.05

 

 

The following provides a reconciliation of the shares used in calculating the per share amounts for the periods presented:

 

 

 

For the Three Months Ended September 30,

(Unaudited)

 

 

 

2021

 

 

2020

 

Numerator:

 

 

 

 

 

 

  Net Income (Loss)

 

$(486,558)

 

$1,019,300

 

Denominator:

 

 

 

 

 

 

 

 

  Basic weighted-average shares

 

 

16,843,045

 

 

 

16,741,622

 

Effect of dilutive securities

 

 

 

 

 

 

 

 

  Warrants

 

 

-

 

 

 

1,686,633

 

  Options

 

 

-

 

 

 

101,250

 

  Preferred Stock

 

 

-

 

 

 

63,750

 

Diluted Weighted Average Shares

 

 

16,843,045

 

 

 

18,593,255

 

Net Income (Loss) Per Common Share:

 

 

 

 

 

 

 

 

Basic

 

$(0.03)

 

$0.06

 

Diluted

 

$(0.03)

 

$0.05

 

 

 

 

 

 

 

 

 

 

Note: Warrants, options and preferred stock for the three months ended September 30, 2021 are not included in the computation of diluted weighted average shares as such inclusion would be anti-dilutive.

 

 

 

For the Nine Months Ended September 30,

(Unaudited)

 

 

 

2021

 

 

2020

 

Net Income (Loss)

 

$(2,775,952)

 

$7,295,478

 

Adjustments for convertible debt - as converted

 

 

 

 

 

 

 

 

Interest on convertible debt

 

 

-

 

 

 

40,689

 

Net income (loss) attributable to common shareholders

 

$(2,775,952)

 

$7,366,167

 

Weighted average number of shares of common stock outstanding:

 

 

 

 

 

 

 

 

Basic

 

 

16,805,145

 

 

 

16,429,360

 

Diluted

 

 

16,805,145

 

 

 

18,280,993

 

Net income (loss) attributable to common shareholders per share:

 

 

 

 

 

 

 

 

Basic

 

$(0.17)

 

$0.45

 

Diluted

 

$(0.17)

 

$0.40

 

 

 

The following provides a reconciliation of the shares used in calculating the per share amounts for the periods presented:

 

 

 

For the Nine Months Ended September 30,

(Unaudited)

 

 

 

2021

 

 

2020

 

Numerator:

 

 

 

 

 

 

  Net Income (Loss)

 

$(2,775,952)

 

$7,295,478

 

Denominator:

 

 

 

 

 

 

 

 

  Basic weighted-average shares

 

 

16,805,145

 

 

 

16,429,360

 

Effect of dilutive securities

 

 

 

 

 

 

 

 

  Warrants

 

 

-

 

 

 

1,686,633

 

  Options

 

 

-

 

 

 

101,250

 

  Preferred Stock

 

 

-

 

 

 

63,750

 

Diluted Weighted Average Shares

 

 

16,805,145

 

 

 

18,280,993

 

Net Income (Loss) Per Common Share:

 

 

 

 

 

 

 

 

Basic

 

$(0.17)

 

$0.44

 

Diluted

 

$(0.17)

 

$0.40

 

 

 

 

 

 

 

 

 

 

Note: Warrants, options and preferred stock for the nine months ended September 30, 2021 are not included in the computation of diluted weighted average shares as such inclusion would be anti-dilutive.

Disaggregation of Revenue

 

 

For the three months ended September 30,

(Unaudited)

 

 

 

2021

 

 

2020

 

SteraMist Product

 

$1,657,000

 

 

$3,677,000

 

Service and Training

 

 

548,000

 

 

 

615,000

 

 Total

 

$2,205,000

 

 

$4,292,000

 

 

Revenue by Geographic Region

 

 

 

For the three months ended September 30,

(Unaudited)

 

 

 

2021

 

 

2020

 

United States

 

$2,028,000

 

 

$3,446,000

 

International

 

 

177,000

 

 

 

846,000

 

 Total

 

$2,205,000

 

 

$4,292,000

 

 

Product and Service Revenue

 

 

 

For the nine months ended September 30,

(Unaudited)

 

 

 

2021

 

 

2020

 

SteraMist Product

 

$4,329,000

 

 

$19,557,000

 

Service and Training

 

 

1,415,000

 

 

 

1,817,000

 

 Total

 

$5,744,000

 

 

$21,374,000

 

 

 

Revenue by Geographic Region

 

 

 

For the nine months ended September 30,

(Unaudited)

 

 

 

2021

 

 

2020

 

United States

 

$5,017,000

 

 

$15,437,000

 

International

 

 

727,000

 

 

 

5,937,000

 

 Total

 

$5,744,000

 

 

$21,374,000